MAPT and Alzheimer disease: According to the Amyloid/Tau/Neurodegeneration (ATN) framework (6), levels of Aβ42/Aβ40 ratio, phospho-tau (pTau) and neurofilament light (Nfl) in the CSF determine the diagnosis of AD biologically.